HomePress-release

Redding, California - March 14, 2024

Continuous Bioprocessing Market to be Worth $1.32 Billion by 2031

Continuous Bioprocessing Market by Product (Filtration, Chromatography, Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream, Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma Fractionation, R&D) End User - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled ‘Continuous Bioprocessing Market by Product (Filtration, Chromatography, Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream, Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma Fractionation, R&D) End User - Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the continuous bioprocessing market is projected to reach $1.32 billion by 2031 at a CAGR of 19.6% from 2024 to 2031.

Process Analytical Technology (PAT) in Continuous Manufacturing—A Recent Trend in the Continuous Bioprocessing Market

Continuous manufacturing represents the next generation of pharmaceutical manufacturing processes for small and large molecules. It has been recognized as a key technology by regulatory authorities. Key market players are integrating process analytics with continuous bioprocessing for efficient continuous manufacturing. PAT systems are analytical tools used to control and monitor manufacturing processes. PAT systems can improve analysis, design, and control in continuous manufacturing. Additionally, PAT systems can help optimize continuous biomanufacturing by providing real-time data on critical quality attributes and process parameters. The real-time data obtained from PAT can be used for data-driven decision-making to make changes in continuous biomanufacturing whenever needed.

The implementation of PAT is increasing due to benefits such as better control over manufacturing processes, increased efficiency, better product quality, cost reduction, and data-driven insights. Additionally, PAT also offers commercial benefits such as reduced waste and rework, less energy consumption, right-first-time manufacturing, flexibility in raw material sourcing, and higher production asset utilization. Market players are collaborating to support the implementation of PAT in continuous bioprocessing. For instance, in June 2022, Merck KGaA (Germany) collaborated with Agilent Technologies, Inc. (U.S.) to advance downstream Process Analytical Technologies (PAT) and enable real-time data release and Bioprocessing 4.0.

Key Players

The key players operating in the continuous bioprocessing market are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Repligen Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), and Meissner Corporation (U.S.).

Continuous Bioprocessing Market: Future Outlook

The continuous bioprocessing market is segmented by Product (Filtration Systems & Consumables, Chromatography Systems & Consumables; Cell Culture Media, Buffers, and Reagents; Incubators & Shakers, Bioreactors, Centrifuges, Sterilizers, and Other Instruments & Consumables), Process Type (Upstream Processes and Downstream Processes), Application (Commercial Applications [Monoclonal Antibodies (mAb) Production, Cell & Gene Therapy Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant Protein Production] and R&D Applications), End User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs) & Contract Research Organizations (CROs), and Academic & Research Institutes), and Geography. The study also evaluates industry competitors and analyzes the market at the regional and country levels.

Among all the products studied in this report, in 2024, the filtration systems & consumables segment is expected to account for the largest share of the continuous bioprocessing market. Filtration systems are used across every step in bioprocessing. Separation using filtration systems is the method of choice across many bioprocessing operations. Also, filtration is critical in upstream, process development, and downstream processes in bioprocessing. Thus, the need for filtration across all bioprocessing steps supports the segment’s large market share.

Among all the process types studied in this report, in 2024, the downstream processes segment is expected to account for the larger share of the continuous bioprocessing market. The segment’s large market share is attributed to the high adoption of continuous-flow manufacturing technologies for downstream processing in antibody production. Additionally, the integration of Process Analytical Technology (PAT) in downstream processing supports the segment’s large market share. The integration of PAT is improving product quality, increasing consistency, and reducing process variability in downstream processing.

Among all the applications studied in this report, in 2024, the commercial applications segment is expected to account for the larger share of the continuous bioprocessing market. Commercial applications are further segmented into vaccine manufacturing, mAb production, recombinant protein production, cell & gene therapy production, and plasma fractionation. In 2024, the mAb production segment is expected to account for the largest share in terms of commercial applications. The segment’s large share is attributed to the increasing approvals for therapeutic antibodies and facility expansions for monoclonal antibody manufacturing. For instance, in January 2022, Eli Lilly and Company (U.S.) invested $452 million (€400 million) in its monoclonal antibody manufacturing site to expand the company’s manufacturing network for biologic active ingredients.

Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the continuous bioprocessing market. The segment’s large market share is primarily attributed to the high adoption of continuous bioprocessing among pharmaceutical & biotechnology players for the commercial manufacturing of biologics and regulatory bodies’ growing interest in continuous bioprocessing. Additionally, facility expansions for the production of biologics support the segment’s large share. For instance, in February 2024, Thermo Fisher Scientific, Inc. (U.S.) expanded its manufacturing facility in St Louis, U.S., to support the manufacturing of biological therapies for rare diseases. The facility expansion increased the company’s capacity to produce complex biological treatments for diseases, including rare disorders, cancer, and autoimmune conditions, from 2,000l to 5,000l.

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and the Rest of Asia-Pacific), Latin America, and the Middle East & Africa.

Among all regions studied in this report, Asia-Pacific is expected to register the highest CAGR during the forecast period. In Asia-Pacific, China is expected to register the highest CAGR during the forecast period. The country’s growing focus on the pharmaceutical and biopharmaceutical industries, rising investments in biosimilars, and support initiatives for CDMOs are driving market growth in China. The market for biopharmaceuticals, supplies, services, and materials in China has expanded rapidly. The government, investors, and companies, both domestic and international, have focused on the country’s growing healthcare markets and opportunities. For instance, in August 2023, AstraZeneca plc (U.K.) signed an mRNA manufacturing deal with CanSino Biologics (China). Under the agreement, CanSino will use its mRNA manufacturing platform to support AstraZeneca in the R&D of certain vaccines.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5079

Key Questions Answered in the Report:

Which are the high-growth market segments in terms of product, process type, application, end user, and region/country?
What was the historical market size for continuous bioprocessing globally?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, challenges, and trends in the global continuous bioprocessing market?
Who are the major players in the global continuous bioprocessing market?
What is the competitive landscape like, and who are the market leaders in the global continuous bioprocessing market?
What are the recent developments in the global continuous bioprocessing market?
What are the various strategies adopted by major players in the global continuous bioprocessing market?
What are the geographical trends? And which are the high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - March 14, 2024

Continuous Bioprocessing Market to be Worth $1.32 Billion by 2031

Continuous Bioprocessing Market by Product (Filtration, Chromatography, Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream, Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma Fractionation, R&D) End User - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies